Increased asymmetric dimethylarginine concentrations in stimulated peripheral blood mononuclear cells

Scandinavian Journal of Immunology

Volumn 65, Issue 6, 2007, Pages 525-529

  Schroecksnadel, K ^a,b   Weiss, G ^b   Stanger, O ^c   Teerlink, T ^d   Fuchs, D ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ATORVASTATIN; CYSTEINE; CYTOKINE; GAMMA INTERFERON; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; SALICYLIC ACID;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TH1 CELL;

ARGININE; CELLS, CULTURED; CONCANAVALIN A; ENZYME INHIBITORS; HEPTANOIC ACIDS; HUMANS; LEUKOCYTES, MONONUCLEAR; MITOGENS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHYTOHEMAGGLUTININS; PYRROLES; SALICYLIC ACID;

EID: 34249280232     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01935.x     Document Type: Article

References (25)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995 274 : 1049 57.
2. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br Med J 2002 325 : 1202.
3. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003 59 : 824 33.
4. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006 26 : 203 28.
5. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000 20 : 1557 64.
6. Stuehlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003 108 : 933 8.
7. Wanby P, Brattstrom L, Brudin L, Hultberg B, Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest 2003 63 : 347 53.
8. Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005 43 : 1124 9.
9. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005 43 : 1130 8.
10. Teerlink T. ADMA metabolism and clearance. Vasc Med 2005 10 (Suppl. 1 S73 81.
11. Stuehlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001 104 : 2569 75.
12. Bode-Boger SM, Scalera F, Martens-Lobenhoffer J. Asymmetric dimethylarginine (ADMA) accelerates cell senescence. Vasc Med 2005 10 (Suppl. 1 S65 71.
13. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999 99 : 3092 5.
14. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003 134 : 53 6.
15. Schroecksnadel K, Frick B, Wirleitner B, Winkler C, Schennach H, Fuchs D. Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 2004 5 : 107 18.
16. Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Schennach H, Fuchs D. Aspirin downregulates homocysteine formation in stimulated human peripheral blood mononuclear cells. Scand J Immunol 2005 62 : 155 60.
17. Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Weiss G, Fuchs D. Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clin Chem Lab Med 2005 43 : 1373 6.
18. de Jong S, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem 2006 353 : 287 9.
19. Frick B, Schrocksnadel K, Neurauter G, Wirleitner B, Artner-Dworzak E, Fuchs D. Rapid measurement of total plasma homocysteine by HPLC. Clin Chim Acta 2003 331 : 19 23.
20. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003 4 : 41 51.
21. Nathan CF. Peroxide and pteridine: a hypothesis on the regulation of macrophage antimicrobial activity by interferon gamma. Interferon 1986 7 : 125 43.
22. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006 184 : 383 8.
23. Schroecksnadel K, Frick B, Fuerhapter C et al. Homocysteine metabolism in stimulated human cells. Pteridines 2004 15 : 62 3.
24. Werner ER, Werner-Felmayer G, Fuchs D et al. Biochemistry and function of pteridine synthesis in human and murine macrophages. Pathobiology 1991 59 : 276 9.
25. Katial RK, Sachanandani D, Pinney C, Lieberman MM. Cytokine production in cell culture by peripheral blood mononuclear cells from immunocompetent hosts. Clin Diagn Lab Immunol 1998 5 : 78 81.